Unknown

Dataset Information

0

[Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].


ABSTRACT: c-MET is considered a promising oncogenic driver in non-small cell lung cancer (NSCLC) after the discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). MET activation including gene mutation, amplification and protein overexpression, all of these are potential therapeutic targets and are associated with poor prognosis. Clinical evidence suggests a role for MET activation as both a primary oncogenic driver in subsets of lung cancer, and as a secondary driver of acquired resistance to EGFR-tyrosine kinase inhibitor (TKI). This review focuses on the MET activation in NSCLC and the latest trials of its treatment.

SUBMITTER: Yu X 

PROVIDER: S-EPMC5999681 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

[Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].

Yu Xiaoqing X   Xu Yanjun Y   Fan Yun Y  

Zhongguo fei ai za zhi = Chinese journal of lung cancer 20170401 4


c-MET is considered a promising oncogenic driver in non-small cell lung cancer (NSCLC) after the discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). MET activation including gene mutation, amplification and protein overexpression, all of these are potential therapeutic targets and are associated with poor prognosis. Clinical evidence suggests a role for MET activation as both a primary oncogenic driver in subsets of lung cancer, and as a secondary driver of  ...[more]

Similar Datasets

| S-EPMC7306460 | biostudies-literature
| S-EPMC6318572 | biostudies-literature
| S-EPMC8802424 | biostudies-literature
| S-EPMC7406436 | biostudies-literature
| S-EPMC5216909 | biostudies-other
| S-EPMC5928373 | biostudies-literature
| S-EPMC4237616 | biostudies-literature
| S-EPMC4828128 | biostudies-literature
| S-EPMC10634863 | biostudies-literature
| S-EPMC5972355 | biostudies-literature